EGFR and colorectal cancer: In RAS mutant colorectal cancer, liquid biopsy has enabled the identification of “neo-RAS-Wild-Type”, a transient phase characterized by the disappearance of RAS mutations, with significant clinical implications for re-sensitization to EGFR blockade.